Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2022 · View financials
Decision snapshot: ALKS stock price vs CTXR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Needs CTXR P/E.
Implied fair value · at ALKS's multiple
Needs EPS (TTM) is negative, ALKS P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALKS FY 2025 (ended Dec 31, 2025) · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Alkermes plc. · implied price per share
Bear
$16.05
Base
$18.89
Bull
$21.72
Citius Pharmaceuticals, Inc. · implied price per share
Bear
$0.09
Base
$0.11
Bull
$0.13
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.16x
0.01x
Net debt / EBITDA
Leverage against operating earnings
-0.80x
0.09x
Cash and equivalents
Liquid reserves on the balance sheet
$587.34M
$4.25M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
ALKS vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
ALKS vs SUPN
Amneal Pharmaceuticals, Inc.
ALKS vs AMRX
Zomedica Corp.
ALKS vs ZOM
Aquestive Therapeutics, Inc.
ALKS vs AQST
ACADIA PHARMACEUTICALS INC
ALKS vs ACAD
AMGEN INC
ALKS vs AMGN
GILEAD SCIENCES, INC.
ALKS vs GILD
AbbVie Inc.
ALKS vs ABBV
$290.73M
$1.00M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
